Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450437 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
A Phase 3 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,539
- Enrollment target
NCT00450437 is a Phase 3 study that has completed, run by Novartis Vaccines. The registered enrollment target is 3,539 participants.
The verdict
NCT00450437, a Phase 3 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,539 participants
- Enrollment target
Study Summary
This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.
Interventions
- BIOLOGICAL MenACWY CRM
- BIOLOGICAL Meningococcal ACWY Conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,539 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450437
The ClinicalTrials.gov registry entry for NCT00450437 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MenACWY CRM is the first listed.
NCT00450437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450437 about?
NCT00450437 is a clinical study titled "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults". This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.
What is the current status of trial NCT00450437?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,539 participants. The study started on 2007-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00450437?
The interventions under investigation include: MenACWY CRM (BIOLOGICAL), Meningococcal ACWY Conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00450437?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.